Efficacy and safety of Lavender aromatherapy on sleep quality and metabolic parameters of patients with diabetes mellitus type II and insomnia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201703117297N3

Enrollment

Registered

2017-10-21

Start date

2017-08-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes-insomnia.

Interventions

Intervention 1: Lavender Essential oil. Intervention 2: almond oil.

Treatment - Drugs

Placebo

Lavender Essential oil

almond oil

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:• Age: 25-65 years old. Fasting Blood Sugar between 70-130. 2 hour post prandial glucose less than 180. HbA1C less than 7. Sleep disorder according to pittsburgh Insomnia Rating Scale more than 5. Exclusion criteria: Any systemic illnesses. Use of sedative or antidepressant drugs. Pregnancy. Lactation. History of allergic reaction to Lavender. History of allergic rhinitis, asthma and respiratory disorders. Anosmia. Headache that start with smell. Cigarette smocking or substance abuse. Hospitalization or surgery within 1 months ago.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pittsburgh Insomnia Rating Scale. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: pittsburgh Insomnia Rating Scale.	—

Secondary

Measure	Time frame
CRP. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: Blood sample.;FBS. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;TG. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;Cholesterol. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;LDL. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;HDL. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;2hPPG. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;Serum Insulin. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;AST. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;ALT. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;Height. Timepoint: before intervention. Method of measurement: meter.;Weight. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: weight scale.;BMI. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: BMI Index.;Waist circumference. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: meter.;Hip circumference. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: meter.;HbA1C. Timepoint: before intervention. Method of measurement: Blood sample.;Cr. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: Blood sample.;Uric acid. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of m	—

Measure

Time frame

CRP. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: Blood sample.;FBS. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;TG. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;Cholesterol. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;LDL. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;HDL. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;2hPPG. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;Serum Insulin. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;AST. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;ALT. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: blood sample.;Height. Timepoint: before intervention. Method of measurement: meter.;Weight. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: weight scale.;BMI. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: BMI Index.;Waist circumference. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: meter.;Hip circumference. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: meter.;HbA1C. Timepoint: before intervention. Method of measurement: Blood sample.;Cr. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of measurement: Blood sample.;Uric acid. Timepoint: before intervention- 4 week after drug- 4 week after placebo. Method of m

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mojtaba Heydari

Shiraz University of Medical Sciences

vcrdep@sums.ac.ir+98 71 3235 7282

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026